In SLE-prone MRL-Fas(lpr) mice, the treatment with DNA derived from bacteria or CpG ODN facilitated the development of SLE and LN in the mice through activating TLR9 in B cells (36, 37). This evidence concerns the gene TLR9 and systemic lupus erythematosus.